Nu Skin slides after posting weak guidance

• Nu Skin (NUS -12.9%) skids after Q4 results and guidance disappoint.
• Organic sales were flat during the quarter. Selling expenses as a percent of revenue increased 50 bps to 42.0%.
• Looking ahead, Nu Skin expects FY17 revenue of $2.26B to $2.30B vs. $2.3B consensus and 2017 EPS of $3.10 to $3.25 vs $3.19 consensus.
• Previously: Nu Skin misses by $0.01, misses on revenue (Feb. 16)